share_log

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

POS AM：修改註冊聲明表
美股SEC公告 ·  04/22 12:38

Moomoo AI 已提取核心訊息

180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the company's previously issued warrants that allow holders to purchase shares of the company's common stock. The warrants, which have an exercise price of $3.23 per share, are exercisable until February 16, 2029. This filing ensures that the information in the registration statement is current and updates the prospectus attached to the Post-Effective Amendment No. 1. The registration statement covers the 242,915 August 2023 Common Warrants and the common stock issuable upon their exercise. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. The company's common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'.
180 Life Sciences Corp. has filed a post-effective amendment to a Form S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The amendment relates to the company's previously issued warrants that allow holders to purchase shares of the company's common stock. The warrants, which have an exercise price of $3.23 per share, are exercisable until February 16, 2029. This filing ensures that the information in the registration statement is current and updates the prospectus attached to the Post-Effective Amendment No. 1. The registration statement covers the 242,915 August 2023 Common Warrants and the common stock issuable upon their exercise. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. The company's common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'.
180 Life Sciences Corp. 已於2024年4月19日向美國證券交易委員會（SEC）提交了對S-1表格註冊聲明的生效後修正案。該修正案涉及公司先前發行的認股權證，允許持有人購買公司普通股。認股權證的行使價爲每股3.23美元，有效期至2029年2月16日。該文件確保註冊聲明中的信息是最新的，並更新了生效後第1號修正案所附的招股說明書。註冊聲明涵蓋2023年8月的242,915份普通認股權證及其行使後可發行的普通股。沒有根據該修正案註冊其他證券，所有適用的註冊費均已在最初提交時支付。該公司的普通股在納斯達克資本市場上交易，股票代碼爲 “ATNF”。
180 Life Sciences Corp. 已於2024年4月19日向美國證券交易委員會（SEC）提交了對S-1表格註冊聲明的生效後修正案。該修正案涉及公司先前發行的認股權證，允許持有人購買公司普通股。認股權證的行使價爲每股3.23美元，有效期至2029年2月16日。該文件確保註冊聲明中的信息是最新的，並更新了生效後第1號修正案所附的招股說明書。註冊聲明涵蓋2023年8月的242,915份普通認股權證及其行使後可發行的普通股。沒有根據該修正案註冊其他證券，所有適用的註冊費均已在最初提交時支付。該公司的普通股在納斯達克資本市場上交易，股票代碼爲 “ATNF”。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間